[Cardiovascular risk prediction and its relationship with metabolic syndrome and emerging serum makers in occupational health surveillance].
OBJECTIVE
To calculate cardiovascular risk according to the American Framingham Coronary Risk Score (FCRS) and the European Systematic Coronary Risk Evaluation (SCORE) methods. To correlate the results with the presence of meta-bolic syndrome (glycemia, triglyceridemia, cholesterolemia, abdominal circumference and blood pressure) and with serum levels of three emerging biomarkers [ultrasensitive reactive C protein (PCRus), homocysteine (Hcy) and lipoproteín (a) (lp (a)].


METHODS
Data were gathered during routine medical surveillance of mostly white collar workers in FREMAP Alcobendas from 2004 to 2006 (n=248).We followed standardized health surveillance protocols as established by the Spanish Health Ministry, along with inclusion of an additional blood sample and measurement of the abdominal circumference.


RESULTS
None of the 248 workers included in our sample was classified as having high or very high risk according to FCRS in contrast to 44.8 % according to SCORE.We observed a strong correlation (r=0.78, p<0.001) between both predictive methods.We also found associations between both methods and metabolic syndrome (p=0.043), and between the FCRS and PCRus (p=0.021) and Hcy (p=0.036).


CONCLUSIONS
Our results suggest that the inclusion of risk predictions based on FCRS and/or SCORE could be recommended for the primary prevention of cardiovascular disease, because of their excellent cost-benefit relationship. However, we do not recommend routine measurement of the biological markers included in this study.
Medicina del Trabajo, Grupo Banco Popular, Abelias, 1, Madrid, 28042, Spain. lreinoso@bancopopular.es.
Luis
L
Reinoso-Barbero
Ana
A
Capapé-Aguilar
Ramón
R
Díaz-Garrido
Catalina
C
Santiago Dorrego
Félix
F
Gómez-Gallego
Fernando
F
Bandrés Moya
D000328:Adult; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis*; D002318:Cardiovascular Diseases / Q000097:blood* / Q000453:epidemiology* / Q000209:etiology; D003430:Cross-Sectional Studies; D005260:Female; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000150:complications*; D008875:Middle Aged; D016272:Occupational Health; D011159:Population Surveillance; D018570:Risk Assessment / Q000379:methods
D015415:Biomarkers; D017270:Lipoprotein(a); D006710:Homocysteine; D002097:C-Reactive Protein